Clovis Oncology (CLVS) Defended at SunTrust
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress
October 7, 2016 8:45 AM EDTRucaparib NDA Dataset to be presented in oral presentation today at ESMO Rucaparib NDA currently under priority review with FDA Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 European Marketing Authorization Application (MAA) submission planned for Q4 2016
BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology (NASDAQ: CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.... More
